Back to results
US 2016/0166526 A1Published application
Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent
AssigneeTakeda Pharmaceutical Company Limited
InventorNAOMI KITAMOTO
Life of this patent
Estimating the term…
Abstract
The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
Claims32
A method for suppressing a peripheral nerve disorder induced by an anti-cancer agent, which comprises administering a compound represented by the formula (I):
- wherein
- R is
- (1) an aliphatic hydrocarbon group optionally having substituent(s),
- (2) an aromatic hydrocarbon group optionally having substituent(s),
- (3) a heterocyclic group optionally having substituent(s),
- (4) a group represented by the formula:
- —OR1 wherein R1 is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), or
- (5) a group represented by the formula:
- wherein R1b and R1c are the same or different and each is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s),
- R0 is a hydrogen atom or an aliphatic hydrocarbon group, or R and R0 in combination may form a bond,
- ring A1 is a cycloalkene optionally substituted by 1 to 4 substituents selected from the group consisting of
- (i) an aliphatic hydrocarbon group optionally having substituent(s),
- (ii) an aromatic hydrocarbon group optionally having substituent(s),
- (iii) a group represented by the formula:
- —OR11 wherein R11 is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), and
- (iv) a halogen atom,
- Ar is an aromatic hydrocarbon group optionally having substituent(s),
- a group represented by the formula:
- is a group represented by the formula:
- and n is an integer of 1 to 4,
- or a salt thereof or a prodrug thereof, or
- a compound represented by the formula (II):
- wherein
- R1′ is
- (1) an aliphatic hydrocarbon group optionally having substituent(s),
- (2) an aromatic hydrocarbon group optionally having substituent(s),
- (3) a heterocyclic group optionally having substituent(s),
- (4) a group represented by the formula:
- —OR1b′ wherein R1b′ is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), or
- (5) a group represented by the formula:
- wherein R1b′ and R1c′ are the same or different and each is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s),
- X is methylene, NH, a sulfur atom or an oxygen atom,
- Y is methylene optionally having substituent(s) or NH optionally having substituent(s),
- ring A′ is a 5- to 8-membered ring optionally having 1 to 4 substituents selected from the group consisting of
- (i) an aliphatic hydrocarbon group optionally having substituent(s),
- (ii) an aromatic hydrocarbon group optionally having substituent(s),
- (iii) a group represented by the formula:
- —OR2′ wherein R2′ is a hydrogen atom or an aliphatic hydrocarbon group optionally having substituent(s), and
- (iv) a halogen atom,
- Ar′ is an aromatic hydrocarbon group optionally having substituent(s),
- a group represented by the formula:
- is a group represented by the formula:
- s is an integer of 0 to 2,
- t is an integer of 1 to 3, and
- the total of s and t is 4 or less;
- provided that when X is methylene, then Y should be methylene optionally having substituent(s),
- or a salt thereof or a prodrug thereof, to a mammal in need thereof.
44 more elements
A method for suppressing a peripheral nerve disorder induced by an anti-cancer agent, which comprises administering a compound represented by the formula (III):
- wherein R1aa is C1-6 alkyl,
- Xaa is methylene or an oxygen atom, and
- Araa is phenyl optionally having 1 or 2 substituent(s) selected from a halogen atom, C1-6 alkyl and C1-6 alkoxy,
- or a salt thereof or a prodrug thereof, to a mammal in need thereof.
1 more element
Dependencies are inferred from the claim text.